ClinicalTrials.gg
CompletedNCT03608410ProWideUpdated Apr 12, 2023

Intensified Follow-up of Lung Cancer Using Weekly Questionnaires Via the Internet

An interventional study of Weekly Internet based PRO questionnaires in Lung Cancer, sponsored by Regional Hospital West Jutland. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-12.

Sponsored by Regional Hospital West Jutland · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
494
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 124 studies in Lung Neoplasms with a site in Denmark — 35 open to participants now, 47 under way, 8 of them phase 3. Lung Neoplasms · Denmark.

Enrollment
22nd of 94
494 · median 158
Started
2018
with 5 others
No phase
46 of 124
14 open now
Registered
60th of 124
by date

Among the 124 studies in Lung Neoplasms with a site in Denmark, this one is the 22nd largest by enrollment of the 94 interventional ones that give a count, is one of 6 that started in 2018, is one of 46 with no phase, and was the 60th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

35 of the 124 studies in Lung Neoplasms with a site in Denmark are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 124 studies in Lung Neoplasms with a site in Denmark, or all of them as a file.
02

Study summary

This randomized controlled trial (RCT) will test if weekly supplementary internet-based self-monitoring of 12 core symptoms can increase survival in Danish lung cancer patients during follow-up or maintenance treatment. A threshold mechanism will automatically send an alert to the hospital in case of alarming or worsening symptoms and the patient will be contacted by the treating clinicians.

Read the detailed description

This multicenter RCT study enrolls patients diagnosed with stage IV og incurable stage III lung cancer who has non-progressive disease at first evaluation scan. Patients in follow-up or maintenance therapy are eligible.

492 patients will be included in the study with 246 patients in each group.

Intervention In the experimental arm, patients will be asked to fill in a web-based Patient Reported Outcome (PRO) questionnaire every week. If one of the reported symptoms worsens and exceed a predefined threshold of severity, a notification is automatically sent to the hospital. A nurse will review til questionnaire and contact the patient for verification of symptoms. If progression of disease is suspected, a CT scan will be made. Otherwise, the nurse will schedule a visit at the clinic for physical examination and evaluation by a clinician. If progressive disease is not suspected, supportive care will be adjusted and the patient will continue follow up according to the usual schedule.

The interventions ends in case of progressive disease.

Evaluation Baseline CT-scan of thorax and upper abdomen is performed prior to initial treatment and an evaluation CT scan at the time of enrolment. CT scans will be repeated for assessing signs of progression due to standard follow-up procedures in both groups. If progressive disease is suspected based on symptom development, the following scan will be rescheduled to as soon as possible.

Quality of life (QoL) will be measured in both groups using EORTC (European Organisation for Research and Treatment of Cancer) QOL-C30 / LC13 and HADS (Hospital Anxiety And Depression Scale) quality of life questionnaires every 2 month during the study period.

Objectives The primary objective is to test if supplementary weekly PRO monitoring increases overall survival in a Danish Lung Cancer population

Monitoring Clinical decisions taken on the basis of PRO notifications will daily be registered in the software system by the clinicians. Patient responses to questionnaires and PRO-notification handling by the clinical staff will be monitored by Primary Investigator.

End points will be entered by local site investigators.

03

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • Patient reported outcomes
  • Internet
  • TelePRO
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with lung cancer (NSCLC and SCLC), who have received induction treatment* for lung cancer and have no sign of progressive disease at first evaluation CT scan.
  2. Patients diagnosed with stage III treated with palliative intention, and stage IV, regardless of treatment intention.
  3. Diagnosis proven by cytology or histology
  4. Age ≥ 18 years
  5. Performance status (PS) ≤ 2 within 15 days before enrolment
  6. First evaluation CT scan performed within four weeks from enrolment
  7. Patient with acess to internet, Mobile phone and E-boks (Danish digital secure mail system)
  8. Patient has given his/her written before any specific procedure from protocol

    • Induction treatment includes:

      • Standard doublet chemotherapy
      • Immunotherapy
      • Targeted therapy
      • Palliative radiotherapy
      • Local treatment of oligometastatic disease, including surgery and stereotactic radiotherapy
      • Any combination of the above-mentioned treatment modalities Patients are eligible regardless of whether they at the time of inclusion continue maintenance treatment or not

Exclusion criteria

Exclusion Criteria:

  1. Progressive disease at first evaluation scan
  2. Persons deprived of liberty or under guardianship or curators
  3. Dementia, mental alteration or psychiatric disease that can compromise from the patient and / or adherence to the protocol and the monitoring of the trial
  4. Pregnant or breastfeeding women
  5. Patient participating in another interventional study during the surveillance period. This is only relevant for studies that might interfere with the intervention. Participation in protocols related only to treatment will not preclude participation in the present study. Cases of doubt will be settled by the protocol committee.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
494 participants (actual)

Study arms

  • Experimental
    PRO intervention

    Weekly PRO questionnaires Quality of life every 2 months

    Other: Weekly Internet based PRO questionnaires

  • No intervention
    Standard of care

    Quality of life every 2 months

Interventions

  • OtherWeekly Internet based PRO questionnaires

    If core symptoms worsen and exceeds a predefined threshold, a PRO-notification is sent to the hospital.

06

What researchers measure

Primary outcomes

  1. Overall survival

    Time frame: 2 years

Secondary outcomes

  1. ECOG (Eastern Cooperative Oncology Group) Performance status at time of progression

    (0-5) 0 - Asymptomatic (Fully active, able to carry on all predisease activities without restriction) 1. - Symptomatic but completely ambulatory (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature. For example, light housework, office work) 2. - Symptomatic, \<50% in bed during the day (Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours) 3. - Symptomatic, \>50% in bed, but not bedbound (Capable of only limited self-care, confined to bed or chair 50% or more of waking hours) 4. - Bedbound (Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair) 5. - Death

    Time frame: 2 years

  2. Progression free survival

    Time frame: 2 years

  3. Type of treatment at time of progression

    Number of patients who are candidates for 2nd line medical antineoplastic treatment

    Time frame: 2 years

  4. Quality of life (QOL) measured by EuroQol EQ-5D-5L.

    EQ-5D-5L measures individual generic health status using 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, and each dimension has 5 levels depending on severity of symptoms (1 no problems, 5 extreme problems) and a VAS (visual analogue scale). The scores can then be converted into a single index number. The index value will be used for calculation of quality-adjusted life years (QALYs) for a health economic analysis of the intervention.

    Time frame: 2 years

  5. Quality of life measured by EORTC QLQ C30/LC13.

    The EORTC QLQ-C30 questionnaire consists of 30 questions with five functional scores (physical, role, cognitive, emotional and social); a global health status score three symptom scale score (fatigue, pain, nausea and vomiting); and six independent one-item scores describing additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation and diarrhea) and financial burden. The EORTC QLQ-LC13 is a supplementary module to the C30 questionnaire and generates a multiple-item scale score of dyspnea and a number of single-item scores that assesses chest pain, arm / shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia and hemoptysis. All scales and single-item scores can be linearly transformed to a score ranged from 0 to 100. A higher score of global health and functional subscriptions indicates better functioning.

    Time frame: 2 years

  6. HADS score (Hospital Anxiety And Depression Scale)

    The HADS (The hospital anxiety and depression scale) is a fourteen-item scale. Seven items relate to depression and seven to anxiety. The tool has been developed for detection of anxiety and depression in patients with physical health problems. All items are scored from 0-3 with a possible total score between 0 and 21 for anxiety and depression respectably. A cut-off point of \>7 for anxiety or depression is considered significant.

    Time frame: 2 years

  7. Qualitative interviews

    Qualitative interviews with members of the clinical staff and a group of patients in the intervention arm will be conducted during the study period. The purpose is to identify barriers, advantages and possible reasons for the outcomes of the study.

    Time frame: 2 years

  8. Baseline questionnaires of non-participants

    All patients who met the inclusion criteria but declined to participate in the trial will be asked to fill in a questionnaire. The questionnaire will include information on socioeconomics, reasons for non-participation and the same HRQoL questionnaires that are filled in by the participants in the trial (EORTC QLQ-C30/LC13, HADS, EQ-5D-5L). The purpose is to identify baseline differences between participants and non-participants and thereby testing the PRO system for generalizability.

    Time frame: 2 years

07

Study locations

1 site
  • Department of oncology, Regional Hospital West Jutland
    Herning, 7400, Denmark
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Sep 2021, 35 months.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's 35 months is close to that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2018
First posted
Aug 1, 2018
StartActual
Sep 18, 2018
Primary completionActual
Sep 1, 2021
CompletionActual
Nov 1, 2022
Last update
Apr 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03608410
Lead sponsor
Regional Hospital West Jutland
Collaborators
Danish Cancer Society, Danish Lung Cancer Group
Responsible party
Rasmus Blechingberg Friis (MD, Principal Investigator, Regional Hospital West Jutland) — Principal investigator
First posted
Aug 1, 2018
Start date
Sep 18, 2018
Primary completion
Sep 1, 2021
Completion
Nov 1, 2022
Last update
Apr 12, 2023

Study contacts

Rasmus Friis, MD
principal investigator · Department of Oncology, Regional Hospital West Jutland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion